Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)

This study is currently recruiting participants.
Verified February 2014 by M.D. Anderson Cancer Center
Sponsor:
Collaborator:
Incyte Corporation
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01751425
First received: December 14, 2012
Last updated: February 3, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: July 2019 (Final data collection date for primary outcome measure)